Novo Nordisk A/S
NVO Healthcare Drug Manufacturers General
Novo Nordisk A/S’s revenue for fiscal 2025 (year ended December 2025) was $46.8 billion, up 11.1% from fiscal 2024. In the quarter to June 2026, revenue grew 4.47%, EPS fell 18.7%, free cash flow grew 71.6% and total debt rose 44.4%, each against the same quarter a year earlier. Revenue growth for ten consecutive years, operating cash flow growth for five.
Follow NVO
Novo Nordisk A/S (NVO) EV/Sales
As of 9 October 2026, Novo Nordisk A/S (NVO) trades at a EV/Sales of 3.6×. Over the past ten years it has ranged from 3.5× (October 2026) to 18.5× (June 2024); the current reading is higher than 1% of that period. That is below the Drug Manufacturers General industry median of 3.9× and in line with the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 5.1× | (44.90%) |
| FY2024 | 9.3× | (31.06%) |
| FY2023 | 13.5× | 9.45% |
| FY2022 | 12.4× | 7.30% |
| FY2021 | 11.5× | 37.92% |
| FY2020 | 8.4× | 12.71% |
| FY2019 | 7.4× | 16.26% |
| FY2018 | 6.4× | (17.32%) |
| FY2017 | 7.7× | 46.14% |
| FY2016 | 5.3× | (42.05%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 4.4× | 23.29% |
| Mar 2026 | 3.6× | (30.52%) |
| Dec 2025 | 5.1× | (6.09%) |
| Sep 2025 | 5.5× | (21.39%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SNY Sanofi compare | 2.0× |
| GSK GSK PLC Sponsored ADR compare | 2.6× |
| BMY Bristol Myers Squibb Company compare | 3.1× |
| PFE Pfizer Inc. compare | 3.3× |
| NVO Novo Nordisk A/S | 3.6× |
| AZN AstraZeneca PLC compare | 4.4× |
| NVS Novartis AG compare | 5.5× |
| GILD Gilead Sciences, Inc. compare | 6.9× |
| AMGN Amgen Inc. compare | 7.0× |
| Drug Manufacturers General industry median | 3.9× |
| Healthcare sector median | 3.6× |
| Market median | 2.2× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)